CY1108211T1 - Προφυλακτικη και θεραπευτικη αγωγη των μολυσματικων, αυτοανοσων και αλλεργικων νοσων με ενωσεις βασης μονοσακχαριτη - Google Patents

Προφυλακτικη και θεραπευτικη αγωγη των μολυσματικων, αυτοανοσων και αλλεργικων νοσων με ενωσεις βασης μονοσακχαριτη

Info

Publication number
CY1108211T1
CY1108211T1 CY20081100772T CY081100772T CY1108211T1 CY 1108211 T1 CY1108211 T1 CY 1108211T1 CY 20081100772 T CY20081100772 T CY 20081100772T CY 081100772 T CY081100772 T CY 081100772T CY 1108211 T1 CY1108211 T1 CY 1108211T1
Authority
CY
Cyprus
Prior art keywords
infectious
autoimmune
based compounds
monosaccharide
prophylactic
Prior art date
Application number
CY20081100772T
Other languages
Greek (el)
English (en)
Inventor
David H Persing
Richard Thomas Crane
Gary T Elliot
J Terry Ulrich
Michael J Lacy
David A Johnson
Jory R Baldridge
Rong Wang
Original Assignee
Corixa Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corporation filed Critical Corixa Corporation
Publication of CY1108211T1 publication Critical patent/CY1108211T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Physical Education & Sports Medicine (AREA)
CY20081100772T 2000-05-19 2008-07-24 Προφυλακτικη και θεραπευτικη αγωγη των μολυσματικων, αυτοανοσων και αλλεργικων νοσων με ενωσεις βασης μονοσακχαριτη CY1108211T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20582000P 2000-05-19 2000-05-19
US28156701P 2001-04-04 2001-04-04
EP01948222A EP1284740B1 (fr) 2000-05-19 2001-05-18 Traitement prophylactique et therapeutique de maladies infectieuses allergiques rt autoimmunes avec des composes a base de monosaccharides

Publications (1)

Publication Number Publication Date
CY1108211T1 true CY1108211T1 (el) 2014-02-12

Family

ID=26900794

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100772T CY1108211T1 (el) 2000-05-19 2008-07-24 Προφυλακτικη και θεραπευτικη αγωγη των μολυσματικων, αυτοανοσων και αλλεργικων νοσων με ενωσεις βασης μονοσακχαριτη

Country Status (21)

Country Link
US (1) US6800613B2 (fr)
EP (2) EP1284740B1 (fr)
JP (1) JP5004261B2 (fr)
KR (1) KR100829674B1 (fr)
CN (1) CN1606446A (fr)
AT (1) ATE395923T1 (fr)
AU (3) AU2001269695B2 (fr)
BR (1) BR0110975A (fr)
CA (1) CA2409221C (fr)
CY (1) CY1108211T1 (fr)
DE (1) DE60134134D1 (fr)
DK (1) DK1284740T3 (fr)
ES (1) ES2305086T3 (fr)
HU (1) HU230847B1 (fr)
IL (3) IL152935A0 (fr)
MX (1) MXPA02011486A (fr)
NO (1) NO331939B1 (fr)
NZ (1) NZ522755A (fr)
PL (1) PL206832B1 (fr)
PT (1) PT1284740E (fr)
WO (1) WO2001090129A2 (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7915238B2 (en) 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US20030105032A1 (en) * 2000-05-19 2003-06-05 Persing David H. Phophylactic and therapeutic treatment of infectious and other diseases with mono-and disaccharide-based compounds
EA200400407A1 (ru) * 2001-09-07 2004-08-26 Дзе Трастиз Оф Бостон Юниверсити Способ и композиция для лечения расстройств, связанных с иммунными комплексами
EP1302206A1 (fr) * 2001-10-11 2003-04-16 Universitair Medisch Centrum Utrecht Procédés et moyens pour l'utilisation du récépteur toll-like adventitiel
KR100858947B1 (ko) * 2002-02-04 2008-09-17 코릭사 코포레이션 면역효과기 화합물을 사용하는 감염성 질환 및 기타질환의 예방학적 및 치료학적 처치
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
IL166178A0 (en) 2002-07-08 2006-01-15 Corixa Corp Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors and intermediates therefor
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
ZA200505302B (en) 2003-01-06 2007-03-28 Corixa Corp Certain aminoalkyl glucosaminide phosphate compounds and their use
US20060263778A1 (en) * 2004-03-05 2006-11-23 Johnson Geoffrey B Animals with reduced body fat and increased bone density
JP2008528032A (ja) * 2005-01-27 2008-07-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 原発性嚢胞性線維症欠陥を標的化する薬剤の効力を性質決定するための方法
EP1874342B1 (fr) 2005-04-26 2018-06-06 Eisai R&D Management Co., Ltd. Compositions et procédés destinés à l'immunothérapie du cancer
GB0510463D0 (en) * 2005-05-23 2005-06-29 Britania Pharmaceuticals Ltd Improvements in or relating to organic materials
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
SI2068918T1 (sl) 2006-09-26 2012-09-28 Infectious Disease Res Inst Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala
US20090215710A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Carbohydrate based toll-like receptor (tlr) antagonists
EP2214692A2 (fr) * 2007-10-31 2010-08-11 Centocor Ortho Biotech Inc. Utilisation d'antagonistes du récepteur 4 de type toll (tlr4) pour le traitement ou la prévention de troubles ostéoarthritiques
PT2437753T (pt) 2009-06-05 2016-11-23 Infectious Disease Res Inst Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
CA2793959C (fr) 2010-03-25 2019-06-04 Oregon Health & Science University Glycoproteines du cmv et vecteurs recombines
JP2013537892A (ja) 2010-09-22 2013-10-07 ザ ユニバーシティー オブ メルボルン 新規な免疫賦活法
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
CA2832109C (fr) 2011-06-10 2021-07-06 Oregon Health & Science University Glycoproteines de cmv et vecteurs recombinants cmv
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (fr) 2011-10-27 2013-05-01 Christopher L. Parks Particules virales dérivées d'un virus enveloppé
US9241988B2 (en) * 2012-04-12 2016-01-26 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof
PT2850431T (pt) 2012-05-16 2018-07-23 Immune Design Corp Vacinas para hsv-2
EP2679596B1 (fr) 2012-06-27 2017-04-12 International Aids Vaccine Initiative Variante de la protéine env du VIH-1
ES2743465T3 (es) * 2013-03-15 2020-02-19 Glaxosmithkline Biologicals Sa Composición que contiene derivados fosfato de aminoalquil glucosaminida tamponados y su uso para potenciar una respuesta inmunitaria
JP6426706B2 (ja) 2013-04-18 2018-11-21 イミューン デザイン コーポレイション がん処置で使用するためのｇｌａ単剤療法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (fr) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Trimères de glycoprotéines d'enveloppe du vih -1 soluble
EP3116480A1 (fr) 2014-03-12 2017-01-18 GlaxoSmithKline Biologicals S.A. Formulation liposomale immunogène
WO2015136479A1 (fr) 2014-03-12 2015-09-17 Glaxosmithkline Biologicals S.A. Compositions liposomales pour administration par voie muqueuse
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2017013603A1 (fr) 2015-07-21 2017-01-26 Glaxosmithkline Biologicals Sa Immunothérapie complémentaire pour la prévention ou le traitement d'une maladie infectieuse
TW201716084A (zh) 2015-08-06 2017-05-16 葛蘭素史克智慧財產發展有限公司 組合物及其用途與治療
WO2017021912A1 (fr) 2015-08-06 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Modulateurs de tlr combinés avec anticorps anti-ox40
WO2017021792A1 (fr) 2015-08-06 2017-02-09 Glaxosmithkline Biologicals Sa Agonistes de tlr4, leurs compositions et leur utilisation dans le traitement du cancer
NZ738202A (en) 2015-12-03 2019-07-26 Glaxosmithkline Ip Dev Ltd Cyclic purine dinucleotides as modulators of sting
WO2017098421A1 (fr) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Composés benzothiadiazine
WO2017153952A1 (fr) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited Dérivés de 5-sulfamoyl-2-hydroxybenzamide
JP6746712B2 (ja) 2016-04-07 2020-08-26 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節因子として有用な複素環式アミド
SG11201808708RA (en) 2016-04-07 2018-11-29 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
CR20180521A (es) 2016-05-05 2019-01-15 Glaxosmithkline Ip No 2 Ltd Inhibidores del potenciador del homólogo zeste 2
WO2018015879A1 (fr) 2016-07-20 2018-01-25 Glaxosmithkline Intellectual Property Development Limited Dérivés d'isoquinoléine utilisés comme inhibiteurs de perk
US20190365710A1 (en) 2016-12-01 2019-12-05 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
US11389465B2 (en) 2017-05-01 2022-07-19 Vanderbilt University Phosphorylated hexaacyl disaccharides (PHADs) for treating or preventing infections
WO2019021208A1 (fr) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited Dérivés d'indazole utiles en tant qu'inhibiteurs de perk
WO2019053617A1 (fr) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Composés chimiques
EP3692033A1 (fr) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulateurs de stimulateur des gènes (sting) d'interféron utiles dans le traitement du vih
CN111417630B (zh) 2017-10-05 2023-06-06 葛兰素史克知识产权开发有限公司 干扰素基因刺激因子(sting)的调节剂
MX2020008417A (es) 2018-02-12 2020-11-11 Inimmune Corp Ligandos de receptores de tipo toll.
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
WO2020031087A1 (fr) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Polythérapie
WO2020030571A1 (fr) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinaisons d'un anticorps pd-1 et d'un modulateur de tlr4 et leurs utilisations
WO2020030570A1 (fr) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinaisons d'un anticorps ox40 et d'un modulateur de tlr4 et leurs utilisations
WO2020109365A1 (fr) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Procédés de fabrication d'un adjuvant
AU2020308053A1 (en) 2019-06-26 2022-01-20 Glaxosmithkline Intellectual Property Development Limited IL1RAP binding proteins
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
EP3999108A1 (fr) 2019-07-21 2022-05-25 GlaxoSmithKline Biologicals S.A. Vaccin viral thérapeutique
WO2021018941A1 (fr) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Méthodes de traitement du cancer
WO2021043961A1 (fr) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Schéma posologique pour le traitement du cancer avec un anticorps agoniste anti-icos et une chimiothérapie
BR112022004228A2 (pt) 2019-09-09 2022-05-31 Glaxosmithkline Biologicals Sa Composições imunoterapêuticas
AU2020355614A1 (en) 2019-09-27 2022-04-14 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins
CN112999233B (zh) * 2019-12-19 2023-10-20 中国医学科学院药物研究所 一类来源于赤芍的单萜苷类化合物及其制法和应用
WO2021245611A1 (fr) 2020-06-05 2021-12-09 Glaxosmithkline Biologicals Sa Protéines modifiées de spicule de coronavirus bêta
EP4245763A1 (fr) * 2020-11-11 2023-09-20 Daiichi Sankyo Company, Limited Nouveau dérivé d'aminoalkyl glucosaminide 4-phosphate
EP4032547A1 (fr) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Fragments dérivés du hsv 1 fce pour le traitement du hsv
AU2022230795A1 (en) 2021-03-02 2023-09-21 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as dnmt1 inhibitors
EP4314060A1 (fr) 2021-03-31 2024-02-07 GlaxoSmithKline Intellectual Property Development Limited Protéines de liaison à l'antigène et leurs combinaisons

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
WO1989001973A2 (fr) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Virus variolique recombinant d'immunisation contre des antigenes associes a une tumeur
EP0324455A3 (fr) * 1988-01-15 1991-03-27 Hans O. Ribi Nouvel adjuvant immunologique polymerique
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0487587A1 (fr) 1989-08-18 1992-06-03 Chiron Corporation Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles
AU660325B2 (en) * 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
EP1167379A3 (fr) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Oligonucléotides immunomodulateurs
US6887483B2 (en) * 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
US5762943A (en) * 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) * 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6355257B1 (en) 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) * 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6368604B1 (en) * 1997-09-26 2002-04-09 University Of Maryland Biotechnology Institute Non-pyrogenic derivatives of lipid A
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
KR20010042573A (ko) 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
CA2333578C (fr) * 1998-07-14 2010-11-16 American Cyanamid Company Compositions d'adjuvants et de vaccins contenant un lipide monophosphoryle a
US6013640A (en) 1998-08-21 2000-01-11 Ribi Immunochem Research, Inc. Phosphoglycolipid and methods for its use
US6261573B1 (en) * 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
DK1127137T4 (da) * 1998-11-03 2014-02-10 Nederlanden Staat LPS med reduceret toksicitet fra genetisk modificerede gram-negative bakterier
JP2003510335A (ja) * 1999-08-06 2003-03-18 コリクサ コーポレイション 自己免疫疾患の処置のためのワクチン
WO2001034794A1 (fr) * 1999-11-10 2001-05-17 Smithkline Beecham Biologicals S.A. Antigene surexprime dans le cancer du colon (casb7434)
US6699846B2 (en) * 2000-03-17 2004-03-02 Corixa Corporation Mono- and disaccharides for the treatment of nitric oxide related disorders

Also Published As

Publication number Publication date
NO20025543D0 (no) 2002-11-19
MXPA02011486A (es) 2004-01-26
PL206832B1 (pl) 2010-09-30
AU2007202117A1 (en) 2007-05-31
EP1284740B1 (fr) 2008-05-21
NZ522755A (en) 2004-05-28
EP2000144A1 (fr) 2008-12-10
WO2001090129A2 (fr) 2001-11-29
KR100829674B1 (ko) 2008-05-16
IL152935A0 (en) 2003-06-24
KR20030031485A (ko) 2003-04-21
US6800613B2 (en) 2004-10-05
AU2001269695B2 (en) 2007-02-15
BR0110975A (pt) 2004-03-23
PL365169A1 (en) 2004-12-27
DE60134134D1 (de) 2008-07-03
JP5004261B2 (ja) 2012-08-22
AU6969501A (en) 2001-12-03
DK1284740T3 (da) 2008-08-04
WO2001090129A3 (fr) 2002-06-06
PT1284740E (pt) 2008-07-09
AU2007202117B2 (en) 2011-01-27
IL186495A0 (en) 2008-01-20
CA2409221C (fr) 2010-10-26
ATE395923T1 (de) 2008-06-15
JP2004508292A (ja) 2004-03-18
CN1606446A (zh) 2005-04-13
ES2305086T3 (es) 2008-11-01
CA2409221A1 (fr) 2001-11-29
HU230847B1 (en) 2018-08-28
NO20025543L (no) 2003-01-08
HUP0301815A3 (en) 2009-08-28
HUP0301815A2 (hu) 2003-09-29
IL152935A (en) 2009-08-03
NO331939B1 (no) 2012-05-07
US20020077304A1 (en) 2002-06-20
EP1284740A2 (fr) 2003-02-26
IL186495A (en) 2010-12-30

Similar Documents

Publication Publication Date Title
CY1108211T1 (el) Προφυλακτικη και θεραπευτικη αγωγη των μολυσματικων, αυτοανοσων και αλλεργικων νοσων με ενωσεις βασης μονοσακχαριτη
CY1118171T1 (el) Θεραπευτικη αντιμετωπιση της φαiνυλκετονουρiας me βη4
ATE542801T1 (de) Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
DE60033530D1 (de) Humane antikörper gegen ctla-4 und deren verwendungen
ATE531382T1 (de) Behandlungsmethoden von entzündungskrankheiten mit spezifisch an menschliches angiopoietin-2 bindenden wirkstoffen
CY1105221T1 (el) Ιατρικη χρηση θυρεοειδομιμητικων ενωσεων για την θepαπευτικη αγωγη της τριχοπτωσης και φαρμακευτικες συνθεσεις
BR0011838A (pt) Elementos misturadores estáticos empilhados
DE3751470T2 (de) Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen.
CY1115745T1 (el) Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
DE60327622D1 (de) Kombinierte antitachykardie - schrittmacher und hochspannungstherapie zur behandlung von ventrikulären arrhythmien
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
FI971756A0 (fi) CD23:een sitoutuvia aineita
EA200300929A1 (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE60236318D1 (de) Präparationen grampositiver bakterien zur behandlung von krankheiten mit immunfehlregulation
CY1119579T1 (el) Μεθοδος για τη θεραπεια διαταραχων αναπτυξης της τριχας, οπως η γυναικειου τυπου αλωπεκια και συνεπως χρησιμα σκευασματα
DE60333205D1 (de) Histaminika zur behandlung von allergischer rhinitis
DE602004026597D1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
MXPA04007491A (es) Tratamiento profilactico y terapeutico de infecciones y otras enfermedades con compuestos inmunoefectores.
DE602004009414D1 (de) BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN MIT N-2,3,3-TETRAMETHYLBICYCLOi2.2.1öHEPTAN-2-AMINE
CY1106740T1 (el) Παραλλαγες του μειζονος αλλεργιογονου par j 2 του φυτου περδικακι
CY1106363T1 (el) Χρηση του ενepγοποιημενου παραγοντα πηξης vii για την αγωγη των επαγομενων απο θρομβολυτικη θepαπεια μειζονων αιμορραγιων
ATE328000T1 (de) Phospholipidester von clofarabin